Drug Manufacturers - General · NYSE
Current Price
$241.52
Intrinsic Value
Use the calculator below to estimate
Run a full DCF analysis on Johnson & Johnson with auto-filled fundamentals, adjustable assumptions, and sensitivity heatmap.
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
ROIC (TTM)
13.7%
ROE (TTM)
33.8%
FCF Yield
3.38%
Based on trailing twelve-month data, JNJ shows a free cash flow per share of N/A and a ROIC of 13.7%, key inputs for stock valuation using the DCF method. The P/FCF ratio of N/A and FCF yield of 3.38% are important context metrics when evaluating JNJ's stock valuation relative to peers.
The intrinsic value of JNJ depends on your assumptions about future growth rate, discount rate (WACC), and terminal value. Use MiniValuator's free DCF stock valuation calculator to estimate it with your own assumptions and see the sensitivity analysis heatmap.
Whether JNJ is undervalued depends on your DCF assumptions. If the calculated intrinsic value is significantly above the current market price, it may be undervalued. The margin of safety indicates the degree of undervaluation. Run a full stock valuation on MiniValuator to find out.
You can value JNJ using MiniValuator's DCF stock valuation calculator: enter the ticker, review auto-filled fundamentals, adjust growth rate and discount rate assumptions, then get an instant intrinsic value with sensitivity heatmap.
DCF (Discounted Cash Flow) stock valuation estimates a company's intrinsic value by discounting projected future free cash flows back to their present value. For JNJ, you input expected growth rates and a discount rate (WACC), and the model calculates what the stock should be worth today based on its future cash generation.
WACC (Weighted Average Cost of Capital) is the discount rate used in JNJ stock valuation. A higher WACC lowers the intrinsic value estimate, while a lower WACC raises it. Use MiniValuator's sensitivity heatmap to see how different WACC assumptions impact the JNJ DCF valuation result.
